Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Taxes (2024 - 2025)

BridgeBio Pharma (BBIO) has disclosed Current Taxes for 2 consecutive years, with $2.1 million as the latest value for Q2 2025.

  • Quarterly Current Taxes changed N/A to $2.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Jun 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2024, N/A changed from the prior year.
  • Current Taxes hit $2.1 million in Q2 2025 for BridgeBio Pharma, up from $1.2 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $2.1 million in Q2 2025 to a low of $1.2 million in Q4 2024.